MEF2D and acute lymphoblastic leukemia: In this work, we provide a proteomics-guided analysis of 49 childhood ALL cell lines, generate a comprehensive resource of biomarkers and drug sensitivities, and identify a potential therapeutic vulnerability to target the MEF2D-HNRNPUL1 rearranged high-risk subgroup.